Solving the map-of-maps or map of collections, often requires creation of
custom data model classes that fit into the json/xml/xsd paradigms.
In xml, a map can be represented as a sequence of complex types that have a key
and some other structure for a value (primitive or otherwise).
<complexType name="StringStringMap">
<sequence>
<element name="stringStringMapEntry" type="map:StringStringMapEntry"
minOccurs="0" maxOccurs="unbounded" />
</sequence>
</complexType>
<complexType name="StringStringMapEntry">
<attribute name="key" type="string" use="required" />
<attribute name="value" type="string" use="optional" />
</complexType>
> On Apr 29, 2024, at 4:46 AM, Vassilis Virvilis
> <v.virvi...@biovista.com.INVALID> wrote:
>
> I am using it.
>
> Although I plan to move to JAX-RS. However, I can't be sure about the
> scheduling...
>
> Aegis is the simplest and most versatile databinding for java first
> development in my opinion.
>
> The others (jax-ws, jaxb and xmlbeans) never worked for me when I had to
> transfer
> Map Of Maps or Map of Collections.
>
> I just wanted to give you my one datapoint. I understand that the developers
> will have to weigh
> carrying around a databinding vs its existing usage vs the development
> effort required.
>
> Vassilis
>
> On 4/22/24 6:06 AM, Jim Ma wrote:
>> Hi all,
>> I am not sure if it's the time to deprecate some old cxf things that no one
>> is using, so I write to get your thoughts/ideas here.
>> The first I can think of is aegis databinding. Is the aegis databinding
>> still used by CXF users ? Is it a good time to deprecate and remove in the
>> future release ?
>>
>> Thanks,
>> Jim
>>
>
> --
>
> __________________________________
>
> Vassilis Virvilis Ph.D.
> Head of IT
> Biovista Inc.
>
> Stay tuned
> www: http://www.biovista.com
> LinkedIn: https://www.linkedin.com/company/biovista
> Twitter: https://twitter.com/BiovistaInc/
> Vizit https://twitter.com/BiovistaVizit/
> Facebook: https://www.facebook.com/biovistainc
> Vizit (research): https://www.facebook.com/BiovistaVizit
> YouTube: https://www.youtube.com/user/BiovistaInc
>
> --
> US Offices
> 2421 Ivy Road
> Charlottesville, VA 22903
> USA
> T: +1.434.971.1141
> F: +1.434.971.1144
>
> European Offices
> 34 Rodopoleos Street
> Ellinikon, Athens 16777
> GREECE
> T: +30.210.9629848
> F: +30.210.9647606
>
> Biovista is a privately held biotechnology company that finds novel uses for
> existing drugs, and profiles their side effects using their mechanism of
> action. Biovista develops its own pipeline of drugs in CNS, oncology,
> auto-immune and rare diseases. Biovista is collaborating with
> biopharmaceutical companies on indication expansion and de-risking of their
> portfolios and with the FDA on adverse event prediction.
>
